Source comparison
TB-500 Side Effects in Studies: Comparison
Equine veterinary trial (JEVS, 2010) 47 horses, 12 weeks Injection-site erythema (8–12%), transient lethargy (15%) Mild, self-limiting None beyond 12 weeks Rodent wound healing model (Wound Repair Regen, 2007) 60 mice, 12 weeks No observable adverse effects at
This comparison does not assign a generated winner or score.
- Equine veterinary trial (JEVS, 2010)
- 47 horses, 12 weeks
- Injection-site erythema (8–12%), transient lethargy (15%)
- Mild, self-limiting
- None beyond 12 weeks
- Rodent wound healing model (Wound Repair Regen, 2007)
- 60 mice, 12 weeks
- No observable adverse effects at 5–10mg/kg
- None reported
- Histological analysis at 12 weeks showed no organ toxicity
- Human Phase II topical formulation (NCT00899054)
- 120 participants, 8 weeks
- Injection-site pain (18%), headache (9%), dizziness (4%)
- Mild to moderate, no discontinuations
- Trial terminated early. No long-term data
- Primate model (unpublished, cited in RegeneRx disclosures)
- 12 primates, 6 weeks
- Mild headache (2 subjects), no systemic effects
- Mild
- None
- Self-reported research use (anecdotal aggregation)
- Estimated 1,000+ individuals
- Injection-site reactions (common), transient flu-like symptoms (rare), headache (occasional)
- Variable, mostly mild
- No systematic tracking exists